Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer.

Carmen Joseph Allegra; Greg Yothers; Michael J. O'Connell; Mark S. Roh; Samia H. Lopa; Nicholas J. Petrelli; Robert W. Beart; Saima Sharif; Norman Wolmark

Journal Article

Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer.

Allegra C
Yothers G
O'Connell M
et al.

Journal of Clinical Oncology (2014) 32(15_suppl) 3603-3603

DOI: 10.1200/jco.2014.32.15_suppl.3603

N/ACitations

16Readers

Get full text

Abstract

3603 Background: The two primary aims of NSABP R-04 were 1) Can the oral fluoropyrimidine, Cape be substituted for the standard of care in the curative setting of St...

Cite

CITATION STYLE

APA

Allegra, C. J., Yothers, G., O’Connell, M. J., Roh, M. S., Lopa, S. H., Petrelli, N. J., … Wolmark, N. (2014). Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer. Journal of Clinical Oncology, 32(15_suppl), 3603–3603. https://doi.org/10.1200/jco.2014.32.15_suppl.3603

Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer.

Abstract

Cite

Register to see more suggestions